Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: An innovative proposal for the treatment of leukemia relapse after cord blood transplantation

Bone Marrow Transplantation

Volumn 38, Issue 9, 2006, Pages 621-627

  Introna, M ^a   Franceschetti, M ^a   Ciocca, A ^a   Borleri, G ^a   Conti, E ^a   Golay, J ^a   Rambaldi, A ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; OKT 3; PERFORIN;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD TRANSFUSION; CELL ISOLATION; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE ACTIVATED KILLER CELL; CYTOTOXICITY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; KILLER CELL; LEUKEMIA CELL; LEUKEMIA RELAPSE; MONONUCLEAR CELL; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; T CELL LYMPHOMA;

ANTIGENS, DIFFERENTIATION; COCULTURE TECHNIQUES; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA; RECURRENCE;

EID: 33750151607     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705503     Document Type: Article

References (28)

1. Tse W, Laughlin MJ. Umbilical cord blood transplantation: A new alternative option. Hematology (Am Soc Hematol Educ Program) 2005, 377-383.
2. Sanz MA. Cord-blood transplantation in patients with leukemia - a real alternative for adults. N Engl J Med 2004; 351: 2328-2330.
3. Bradley MB, Cairo MS. Cord blood immunology and stem cell transplantation. Hum Immunol 2005; 66: 431-446.
4. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
5. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
6. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696.
7. Hoyle C, Bangs CD, Chang P, Kamel 0, Mehta B, Negrin RS et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92: 3318-3327.
8. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoictic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222.
9. Sehmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 199 1; 174: 139-149.
10. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97: 2923-2931.
11. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-1679.
12. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaernic blasts. Br J Haematol 2002; 116: 78-86.
13. Sconocchia G, Lau M, Provenzano M, Rezvam K, Wongsena W, Fujiwara H et al. The antileukernia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005; 106: 3666-3672.
14. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA et al. Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001; 7: 532-542.
15. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS et al. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003; 101: 640-648.
16. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999; 9: 12044-12049.
17. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187.
18. Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB et al. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002; 8: 464-468.
19. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1146-1151.
20. Derzic S, Slone V, Sender L. IL-2-activated cord blood mononuclear cells. Cytotherapy 2005; 7: 408-416.
21. Parmar S, Robinson S, Komanduri K, St John L, Decker W, Xing D et al. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 2006; 8: 149-157.
22. Tomizawa D, Aoki Y, Nagasawa M, Morio T, Kajiwara M, Sekine T et al. Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. Eur J Haematol 2005; 75: 441-444.
23. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004; 103: 3065-3072.
24. Introna M, Barbui AM, Golay J, Rambaldi A. Innovative cell-based therapies in onco-hematology: What are the clinical facts? Haematologica 2004; 89: 1253-1260.
25. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
26. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E el al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63-72.
27. Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 2003; 31: 903-910.
28. Mesel-Lemoine M, Cherai M, Le Gouvello S, Guillot M, Leclercq V, Klatzmann D et al. Initial depletion of regulatory T cells: The missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood 2006; 107: 381-388.